Biomarkers

The FDA approved the FoundationOne Liquid CDx based on analytical and clinical validation studies that included more than 7500 samples and 30,000 unique variants across over 30 cancer types.

The recommendations were developed on the basis of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) ranking for genomic alterations occurring in the 8 cancers responsible for the most deaths worldwide.

The FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with any solid malignant neoplasm.

The director of Molecular Pathology and assistant professor of Pathology at Cedars-Sinai spoke about the use of NGS testing to match patients with targeted therapy.

The FDA approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors.

In this interview, Dr. Sumithra J. Mandrekar talks about umbrella versus basket trials in lung cancer.

To assess a patient's risk for breast cancer returning or whether adjuvant therapy would be beneficial, a breast cancer assay can provide important biological information to determine the best course of treatment.

In this interview, we are discussing the use of DNA repair deficiency as a biomarker in breast cancer.